155 related articles for article (PubMed ID: 30664691)
1. Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.
Luna Velez MV; Verhaegh GW; Smit F; Sedelaar JPM; Schalken JA
Oncogene; 2019 May; 38(19):3696-3709. PubMed ID: 30664691
[TBL] [Abstract][Full Text] [Related]
2. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA
Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567
[TBL] [Abstract][Full Text] [Related]
3. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
4. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
[No Abstract] [Full Text] [Related]
6. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
7. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
8. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
9. Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.
Wang B; Lo UG; Wu K; Kapur P; Liu X; Huang J; Chen W; Hernandez E; Santoyo J; Ma SH; Pong RC; He D; Cheng YQ; Hsieh JT
Int J Cancer; 2017 Nov; 141(10):2121-2130. PubMed ID: 28722220
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
11. The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7.
Stockley J; Markert E; Zhou Y; Robson CN; Elliott DJ; Lindberg J; Leung HY; Rajan P
Sci Rep; 2015 Aug; 5():13426. PubMed ID: 26310125
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
13. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
14. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
Duan L; Chen Z; Lu J; Liang Y; Wang M; Roggero CM; Zhang QJ; Gao J; Fang Y; Cao J; Lu J; Zhao H; Dang A; Pong RC; Hernandez E; Chang CM; Hoang DT; Ahn JM; Xiao G; Wang RT; Yu KJ; Kapur P; Rizo J; Hsieh JT; Luo J; Liu ZP
Nucleic Acids Res; 2019 Dec; 47(22):11623-11636. PubMed ID: 31647098
[TBL] [Abstract][Full Text] [Related]
15. AR-V7 expression facilitates accelerated G2/M phase transition in castration-resistant prostate cancer.
Saini T; Gupta P; Raut R; Nayak V; Bharathnaveen P; Mishra P; Misra A
Exp Cell Res; 2024 May; 438(1):114026. PubMed ID: 38604522
[TBL] [Abstract][Full Text] [Related]
16. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
Yi Q; Han X; Yu HG; Chen HY; Qiu D; Su J; Lin R; Batist G; Wu JH
Oncogene; 2024 May; 43(20):1522-1533. PubMed ID: 38532114
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells.
Wang L; Gong S; Zhang X; Azhar Z; Chen J
Gene; 2023 May; 866():147330. PubMed ID: 36871670
[TBL] [Abstract][Full Text] [Related]
18. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
19. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
20. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
